COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma-Reference-Cited by-同舟云学术

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

Published:2014-05-20 Issue:15_suppl Volume:32 Page:9011-9011
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Long Georgina V.¹,Stroyakovsky Daniil L.²,Gogas Helen³,Levchenko Eugeny⁴,de Braud Filippo⁵,Larkin James M. G.⁶,Garbe Claus⁷,Jouary Thomas⁸,Hauschild Axel⁹,Grob Jean Jacques¹⁰,Chiarion-Sileni Vanna¹¹,Lebbe Celeste¹²,Mandalà Mario¹³,Millward Michael¹⁴,DeMarini Douglas James¹⁵,Irani Jhangir G¹⁶,Le Ngocdiep¹⁷,Casey Michelle¹⁶,Patel Kiran¹⁶,Flaherty Keith¹⁸

Affiliation:

1. Melanoma Institute Australia, Sydney, Australia

2. Moscow City Oncology Hospital, Chemotherapy Department, Moscow, Russia

3. University of Athens, Athens, Greece

4. Petrov Research Institute of Oncology, Saint Petersburg, Russia

5. Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

6. Royal Marsden Hospital, London, United Kingdom

7. Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany

8. Saint André Hospital CHU de Bordeaux, Dermatology, Bordeaux, France

9. University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

10. Service de Dermatologie, Centre Hospitalo-Universitaire Sainte-Marguerite, Marseille, France

11. IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy